COVAX to distribute more than 330 million Covid-19 vaccine doses to developing nations
C

COVAX to distribute more than 330 million Covid-19 vaccine doses to developing nations

In one Interim distribution scheme Published on Wednesday, the COVAX vaccine-sharing facility said the dose would cover an average of 3.3% of the total population of 145 countries participating in the initial phase of delivery.

The COVAX initiative was launched in April last year to ensure the rapid and equitable delivery of coronavirus vaccines to immunized rich and poor countries alike and to high-risk groups.

Led by the World Health Organization and several other international health groups, it has since joined 190 countries, but was shocked by the United States, as former President Donald Trump did not want to work with the WHO.

The first round of distribution includes 336 million doses of the AstraZeneca-Oxford vaccine – 240 million by the Serum Institute of India and 96 million by the AstraZeneca – as well as 1.2 million doses of the Pfizer-BioNotech vaccine.

The documents state that the scheme is “non-binding and may be subject to change”, with actual allocation and distribution on WHO’s approval of emergency use and countries’ readiness to receive and administer vaccines. , The document said.

Interim forecasting allowed countries to begin their own vaccination strategies, including storage, distribution, databases and how to address vaccine inhibition, said Dale Fisher, an infectious disease specialist at the National University of Singapore.

“If they know that some doses are coming in the next month or two, then it’s time to start getting everything ready,” he said.

The COVAX initiative currently requires two doses to provide complete immunity to both vaccines. The Pfizer-BioNotech vaccine should be stored at minus 75 ° C, or minus 103 ° F. In comparison, the AstraZeneca-Oxford vaccine can be kept at a refrigerator temperature of 2C to 8C (36F to 46F) for at least six months, making transportation and distribution much easier, especially in developing countries that have cold storage. There is a lack of capacity.

But the Pfizer-BioNTech vaccine is the only one that has received emergency use approval from the WHO. An evaluation of the AstraZeneca-Oxford vaccine is currently underway.

According to the allocation plan, delivery of the AstraZeneca-Oxford vaccine is anticipated to begin in late February if all requirements are met.

“We will soon start distributing life-saving vaccines globally, a result we know is necessary to be able to defeat this pandemic,” said Geth Alliance Chief Executive Seth Berkeley. One of the co-leads of the WHO as well as vaccines for poor countries and initiatives.

EU regulator recommends authorization of AstraZeneca's Kovid-19 vaccine
According to COVAX, Vaccines will be allocated to the participating countries in proportion to the size of their population. For example, India would receive 97 million doses of the AstraZeneca-Oxford vaccine produced by the Serum Institute of India.

North Korea is also included in the list, receiving approximately 2 million doses of the AstraZeneca-Oxford vaccine. Pyongyang claims that the country has not contracted a single case of Kovid-19 – which experts say is untrue.

Some wealthy, self-financed countries were also included in the initial distribution plan, such as South Korea, Canada, New Zealand and Singapore.

COVAX aims to deliver 2 billion doses of coronovirus vaccine in less developed countries by the end of this year, enough to vaccinate more than 20% of its member countries population.

But it has long been a question whether it can achieve that goal due to challenges in obtaining sufficient funds and supplies.

Developed countries have purchased most initial doses of available vaccines. But even they have faced problems in ensuring delivery. The european union has to become Engaged in public dispute with Pfizer-BioNotech and AstraZeneca over alleged delay in vaccine delivery. Last week, the European Commission announced New restrictions That the Kovid-19 vaccines were manufactured in block subject to export authorization – although COVAX is excluded from export control.

Fisher, an expert at the National University of Singapore, said that given the unprecedented scale of the vaccine project, it is bound to face some setbacks.

“I don’t think you would be surprised if there were some communication breakdowns, some expectations not met, and a little competition and funding issues,” he said.

“Because it’s a huge scale of hundreds of millions – and then billions – trying to get into the arms of 8 billion people during an epidemic. It’s really complicated.”

Additional reporting by Reuters.

.


Source

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Yankees Manager Takes Leave of Absence to Get Pacemaker

Yankees Manager Takes Leave of Absence to Get Pacemaker Yankees manager Aaron boon He said that he is expected to be absent from the team...

Passed Over 3 Times by the Marines, a Black Colonel Is Being Promoted

Passed Over 3 Times by the Marines, a Black Colonel Is Being Promoted WASHINGTON - The Marine Corps is promoting the Brigadier General to Colonel...

Chris Harrison says he’s sorry in ‘GMA’ interview but doesn’t explain why he defended contestant’s antebellum photos

Chris Harrison says he's sorry in 'GMA' interview but doesn't explain why he defended contestant's antebellum photos Harrison spoke with "Good Morning America" ​​co-host...

Unemployment claims remain high, even as reopenings gain pace.

Unemployment claims remain high, even as reopenings gain pace. The economy continues to rebound slowly from the worst of the epidemic, but claims for unemployment...